Biotech Values

[zipjet]

>>In all likelihood, generic Lovenox will have a lower patient co-pay than branded Lovenox in most insurance plans and formularies.

I would have thought that most of the Lovenox useage took place in hospitals where payment of the hospital depended more on DRG's or set payment per procedure in agreements with the third party payers.

No doubt doctors still influence what is used. But if I have the economic incidence right, I would think that a hospital would be benefited it they can substitute a generic at lower cost and (big assumption here) it did not change the reimbursement or more likely the adjustment favored the use of generics while capturing part of the delta to the TPP.

ij